The EU Biotech Act II: A vital Act for biomanufacturing in Europe

Joint position paper highlights the need for a dedicated and globally ambitious legislation to deliver biomanufacturing scale‑up and market deployment in Europe

Almost 40 European, national and regional industry organisations have united to reinforce the critical importance of the Biotech Act II. A joint position paper highlights the need for a dedicated and globally ambitious legislation to deliver biomanufacturing scale‑up and market deployment in Europe.

Europe remains the only major global region without a dedicated biomanufacturing initiative. At a time when global competitors such as the United States, India and China are prioritising biomanufacturing at the highest strategic level, the signatories call for a growth and market‑focused EU Biotech Act II to strengthen competitiveness, resilient value chains and high‑quality employment across Europe.

Actions, including the EU Biotech Act Part I which primarily targets health, have boosted innovation, but a critical gap persists in translating innovation into industrial scale in all sectors.

Signatories will continue to work together to support a shared vision for Europe’s industrial future and to ensure that biomanufacturing plays its full role in delivering long‑term growth and resilience.

Dr. Claire Skentelbery, Director General of EuropaBio commented: “A Biotech Act II dedicated to biomanufacturing is the missing piece of the puzzle for the EU’s global competitiveness from this vital technology. It is essential that we empower all sectors with a thriving EU market, cutting edge capability and ensuring that it is the logical next investment for companies in our champion sectors. We must create our own destiny for biomanufacturing, rather than watching it being delivered elsewhere and the job is not yet done.

Download: Joint Industry Statement – The EU Biotech Act II: A vital Act for biomanufacturing in Europe

About EuropaBio

EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European
biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life; to prevent, diagnose, treat, and cure diseases; to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents corporate and associate members, plus national biotechnology associations and bioregions. Read more about our work at www.europabio.org.

Source

EuropaBio, press release, 2026-04-02.

Supplier

EuropaBio

Share

Renewable Carbon News – Daily Newsletter

Subscribe to our daily email newsletter – the world's leading newsletter on renewable materials and chemicals

Subscribe